US · SNY · DRUG MANUFACTURERS - GENERAL
Sanofi (SNY) intrinsic value and stock valuation
$46.52as of 2026-11-21 · Mkt cap 102.72B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Sanofi DCF and intrinsic value
InvestorsCraft values SNY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SNY’s statements →
Sanofi Graham Number
Graham Number: $46.00d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Amgen Inc. (AMGN) $435.64
- Gilead Sciences, Inc. (GILD) $166.43
- Pfizer Inc. (PFE) $27.40
- Bristol-Myers Squibb Company (BMY) $58.80
- CVS Health Corp. (CVS) $80.84
- Vertex Pharmaceuticals Incorporated (VRTX) $515.02
- Medtronic plc (MDT) $99.94
- GSK plc (GSK) $47.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $46.7B | $44.3B | $41.6B | $40.6B | $39.2B |
| Operating income | $9.6B | $7.25B | $6.96B | $10.2B | $8.13B |
| Net income | $7.81B | $5.56B | $5.4B | $8.37B | $6.22B |
| EPSd | $3.2M | $2.22M | $2.15M | $3.34M | $2.48M |
| Operating cash flow | $12.1B | $9.08B | $10.3B | $10.5B | $10.5B |
| Capital expenditure | -$-1.99B | -$-3.2B | -$-1.62B | -$-2.2B | -$-2.04B |
| Free cash flow | $10.1B | $5.89B | $8.64B | $8.33B | $8.48B |
| Total assets | $126.8B | $132.8B | $126.5B | $126.7B | $120.2B |
| Total debt | $20.3B | $17.9B | $18.7B | $21.2B | $22.4B |
| Net debt | $12.7B | $10.5B | $9.99B | $8.48B | $12.3B |
| Total equity | $71.7B | $77.9B | $74.4B | $75.2B | $69B |
| Cash and short-term investments | $8.47B | $7.93B | $8.71B | $12.7B | $10.1B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $46.7B | $44.3B | $41.6B | $40.6B | $39.2B |
| Cost of revenue | $13B | $13.2B | $12.6B | $11.9B | $12.3B |
| Gross profit | $33.7B | $31.1B | $29B | $28.7B | $26.9B |
| Research and development expenses | $7.84B | $7.39B | $6.51B | $6.5B | $5.69B |
| Selling, general and administrative expenses | $10.2B | $9.18B | $8.93B | $8.74B | $9.56B |
| Other expenses | $5.99B | $7.25B | $6.59B | $3.28B | $3.55B |
| Operating expenses | $24.1B | $23.8B | $22B | $18.5B | $18.8B |
| Cost and expenses | $37.1B | $37B | $34.7B | $30.4B | $31B |
| Interest income | $331M | $457.5M | $530.5M | $169M | $3.13M |
| Interest expense | $626M | $622.6M | $512.8M | $384.8M | $377.4M |
| Depreciation and amortization | $5.68B | $3.59B | $4.43B | $3.11B | $3.35B |
| Ebitda | $12.5B | $11B | $11.4B | $13.5B | $11.5B |
| Operating income | $9.6B | $7.25B | $6.96B | $10.2B | $8.13B |
| Total other income/expenses, net | -$-3.58B | -$-494M | -$-845M | -$-170M | -$-289M |
| Income before tax | $6.02B | $6.76B | $6.12B | $9.99B | $7.84B |
| Income tax expense | $1.04B | $1.2B | $1.02B | $1.91B | $1.56B |
| Net income | $7.81B | $5.56B | $5.4B | $8.37B | $6.22B |
| Weighted average shares outstanding | $2.44B | $2.5B | $2.5B | $2.5B | $2.51B |
| Weighted average diluted shares outstanding | $2.44B | $2.5B | $2.51B | $2.5B | $2.51B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $8.47B | $7.93B | $8.71B | $12.7B | $10.1B |
| Net receivables | $11B | $10.6B | $11B | $10.7B | $9.79B |
| Inventory | $10.2B | $9.43B | $9.67B | $8.96B | $8.72B |
| Total current assets | $31B | $42.6B | $30.7B | $34B | $30.6B |
| Property, plant and equipment, net | $11.5B | $11.6B | $11.8B | $11.7B | $12B |
| Goodwill and intangible assets | $67.6B | $66B | $73.7B | $71.5B | $69.5B |
| Long-term investments | $6.61B | $3.26B | $3.26B | $3.22B | $2.91B |
| Total non-current assets | $95.9B | $90.2B | $95.8B | $92.7B | $89.7B |
| Total assets | $126.8B | $132.8B | $126.5B | $126.7B | $120.2B |
| Accounts payable | $7.36B | $7.55B | $7.33B | $6.81B | $6.18B |
| Short-term debt | $4.61B | $4.47B | $2.6B | $4.45B | $3.45B |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $264M | $319M |
| Total current liabilities | $28.3B | $29.2B | $24.2B | $24B | $21.3B |
| Long-term debt | $15.7B | $13.4B | $16.1B | $16.8B | $19B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $26.8B | $25.8B | $27.9B | $27.6B | $29.9B |
| Capital lease obligations | $1.74B | $1.91B | $2.03B | $1.9B | $1.84B |
| Total liabilities | $55.1B | $54.9B | $52.1B | $51.6B | $51.2B |
| Common stock | $2.44B | $2.53B | $2.53B | $2.52B | $2.53B |
| Retained earnings | $0.00 | $0.00 | $67.5B | $66.7B | $63B |
| Accumulated other comprehensive income (loss) | $64.4B | $70.6B | $4.88B | $6.11B | $3.55B |
| Total equity | $71.7B | $77.9B | $74.4B | $75.2B | $69B |
| Total investments | $7.42B | $3.75B | $3.26B | $3.22B | $2.91B |
| Total debt | $20.3B | $17.9B | $18.7B | $21.2B | $22.4B |
| Net debt | $12.7B | $10.5B | $9.99B | $8.48B | $12.3B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $5.57B | $5.5B | $5.4B | $8.37B | $6.22B |
| Depreciation and amortization | $6.46B | $3.59B | $3.78B | $3.42B | $3.35B |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $245M | $244M |
| Change in working capital | $2.03B | -$-615M | $764M | -$-707M | $1.41B |
| Accounts receivable | -$-1.36B | -$-28M | -$-397M | -$-777M | $185M |
| Inventory | -$-44.02M | -$-477M | -$-840M | -$-927M | -$-357M |
| Accounts payable | $449.2M | $789M | $402M | $452M | $451M |
| Net cash provided by operating activities | $12.1B | $9.08B | $10.3B | $10.5B | $10.5B |
| Investments in property, plant and equipment | -$-4.08B | -$-3.24B | -$-3.25B | -$-2.2B | -$-2.04B |
| Acquisitions, net | $955.9M | -$-2.52B | $1.01B | -$-858M | -$-5.59B |
| Net cash used for investing activities | -$-2.76B | -$-4.41B | -$-6.2B | -$-2.08B | -$-7.3B |
| Common stock issued | $199.8M | $187M | $195M | $188M | $186M |
| Common stock repurchased | -$-5.68B | -$-302M | -$-593M | -$-497M | -$-382M |
| Dividends paid | -$-5.39B | -$-4.7B | -$-4.45B | -$-4.17B | -$-4.01B |
| Net cash used for financing activities | -$-9.26B | -$-5.76B | -$-8.05B | -$-5.82B | -$-7.06B |
| Net change in cash | $970.5M | -$-1.27B | -$-4.03B | $2.64B | -$-3.82B |
| Cash at end of period | $8.68B | $7.44B | $8.71B | $12.7B | $10.1B |
| Operating cash flow | $12.1B | $9.08B | $10.3B | $10.5B | $10.5B |
| Capital expenditure | -$-1.99B | -$-3.2B | -$-1.62B | -$-2.2B | -$-2.04B |
| Free cash flow | $10.1B | $5.89B | $8.64B | $8.33B | $8.48B |
Line items
Line items
Line items
About Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
- CEO
- Belén Garijo López
- Employees
- 76.49K
- Beta
- 0.28
Explore
Frequently asked questions
What is the intrinsic value of Sanofi (SNY)?
Sanofi (SNY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SNY undervalued?
SNY trades at a price of $46.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.